ScholarLens Back to search
2007•The Journal of Clinical PsychiatryRequires access

Comparison study of aripiprazole and haloperidol in treatment of schizophrenia

Jiang Kai-d

Open publisher page 0 citations

Abstract

Objective:To compare the efficacy and safety of aripiprazole and haloperidol in treatment of schizophrenia.Method:Antipsychotic efficacy was assessed by positive and negative symptom scale(PANSS)and clinical global impressions-severity of illness rating scale(CGI-SI),antipsychotic side effect was assessed by treatment emergent symptom scale(TESS)and rating scale for extrapyrarnidal side effects(RSESE)in 50 patients treated by aripiprazole(aripiprazole group)and 48 patients treated by haloperidol(haloperidol group)for six weeks.Results:The efficacy was similar in two groups.The reduction of total negative score in patients of aripiprazole group was significantly higher than that in haloperidol group after 4 and 6 weeks.Patients in aripiprazole group had significantly less side effects.Conclusion:Aripiprazole is an effective and safe antipsychotic.

About this research paper

What this paper is about

Objective:To compare the efficacy and safety of aripiprazole and haloperidol in treatment of schizophrenia.Method:Antipsychotic efficacy was assessed by positive and negative symptom scale(PANSS)and clinical global impressions-severity of illness rating scale(CGI-SI),antipsychotic side effect was assessed by treatment emergent symptom scale(TESS)and rating scale for extrapyrarnidal side effects(RSESE)in 50 patients treated by aripiprazole(aripiprazole group)and 48 patients treated by haloperidol(haloperidol group)for six weeks.Results:The efficacy was similar in two groups.The reduction of total negative score in patients of aripiprazole group was significantly higher than that in haloperidol group after 4 and 6 weeks.Patients in aripiprazole group had significantly less side effects.Conclusion:Aripiprazole is an effective and safe antipsychotic.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective:To compare the efficacy and safety of aripiprazole and haloperidol in treatment of schizophrenia.Method:Antipsychotic efficacy was assessed by positive and negative symptom scale(PANSS)and clinical global impressions-severity of illness rating scale(CGI-SI),antipsychotic side effect was assessed by treatment emergent symptom scale(TESS)and rating scale for extrapyrarnidal side effects(RSESE)in 50 patients treated by aripiprazole(aripiprazole group)and 48 patients treated by haloperidol(haloperidol group)for six weeks.Results:The efficacy was similar in two groups.The reduction of total negative score in patients of aripiprazole group was significantly higher than that in haloperidol group after 4 and 6 weeks.Patients in aripiprazole group had significantly less side effects.Conclusion:Aripiprazole is an effective and safe antipsychotic.

Key concepts: Aripiprazole, Haloperidol, Schizophrenia (object-oriented programming), Antipsychotic, Rating scale, Psychology, Antipsychotic Agent, Medicine

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Comparison study of aripiprazole and haloperidol in treatment of schizophrenia — Research Paper | ScholarLens